Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
about
Antidepressants for depression in adults with HIV infectionPhysiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationPhysiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.The majority of hepatitis C patients treated with direct acting antivirals are at risk for relevant drug-drug interactions.Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Validation of Computational Approaches for Antiretroviral Dose OptimizationAntiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation.Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling.Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective
P2860
Q24194669-E543300F-418A-4018-8120-5BB323D9DC0CQ28088352-ABCC81DB-7F37-4739-8180-162AE8BC2580Q35668556-961A79BA-187E-4C15-9BE3-82CCDEA3D141Q36599597-FD1A80B8-207C-4739-8098-892CA77286ABQ38346846-9043B360-99C9-4408-BD50-A68E4002CBC9Q38420688-AB45886B-0CAD-4FC4-A3BE-DB86BF5E78FEQ38435908-2CCDE434-FCE8-4F76-BE42-EE1F1C6E5F49Q38621245-F5DF7248-AE0A-4BAF-99E2-1D7403E89580Q39040977-9443638A-7427-494B-B193-6321B45A98E2Q39418438-F541FDD6-521A-4DB4-B4DB-FD7FBE6ABBDAQ39863986-E5D8A6B7-5418-4214-873A-22B3076531F3Q46448056-57134DD7-6675-45A7-A019-C0BF857B079CQ47186417-EEC27DD1-1BE9-4344-874D-2D4591207ED5Q47267937-D5A9D811-6894-423B-84FF-716304F1AA85Q47592224-8C3A5BD7-F070-48CD-BB95-5F7B8AB5625DQ48524975-1B2FCFC4-574F-4A91-AC47-6CB55029849DQ51051365-A32707A9-922A-4306-8E71-3E27BAAE479BQ54316808-93A58831-0283-4B37-97F4-F9F024A130D6Q58073610-26632FA0-8FA9-4B31-ACE3-0F719F2BA3B6
P2860
Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Prediction of drug-drug intera ...... acokinetic modelling approach.
@en
Prediction of drug-drug intera ...... acokinetic modelling approach.
@nl
type
label
Prediction of drug-drug intera ...... acokinetic modelling approach.
@en
Prediction of drug-drug intera ...... acokinetic modelling approach.
@nl
prefLabel
Prediction of drug-drug intera ...... acokinetic modelling approach.
@en
Prediction of drug-drug intera ...... acokinetic modelling approach.
@nl
P2093
P2860
P1476
Prediction of drug-drug intera ...... acokinetic modelling approach.
@en
P2093
Anna Kirov
Catia Marzolini
David Back
Lisa Almond
P2860
P2888
P304
P356
10.1007/S40262-013-0056-7
P577
2013-07-01T00:00:00Z